|
|
|
|
|
The OLYMPUS Study: Mitomycin Gel for Low-grade Upper Tract Urothelial Cancer
|
|
Seth Paul Lerner, MD, FACS
|
| Seth Lerner, the principal investigator of the OLYMPUS trial reviews the Lancet Oncology publication, the FDA approval of Mitomycin gel for UTUC, and patient selection for this treatment.
|
|
|
|
|
|
|
|
|
|
|
|
|
Neoadjuvant Vs. Adjuvant Chemotherapy in Upper Tract Urothelial Carcinoma
|
|
Alison J. Birtle, MD, MBBS, MRCP, FRCR, BSc
|
| Alison Birtle and Surena Matin join Ashish Kamat for an educational session on the highly debated question of “should we use neoadjuvant or adjuvant therapy when it comes to upper tract urothelial carcinoma?”
|
|
|
|
|
|
|
|
|
|
|
|
|
Developments in Treatment Options for Localized and Advanced Upper Tract Disease
|
Vitaly Margulis, MD
Vitaly Margulis joins Ashish Kamat in a discussion on the top three developments in upper tract urothelial treatment starting with localized disease and moving onto the more advanced disease.
|
|
|
|
|
|
|
|
|
|
|
|
|
|
EDITOR SELECTED ABSTRACTS AND COMMENTARIES |
|
|
|
|
| Intra-Luminal Therapy for Patients with Low-Grade Upper Tract Urothelial Carcinoma
|
| Christopher J.D. Wallis, MD, PhD and Zachary Klaassen, MD, MSc
|
| Upper tract urothelial carcinoma, which may affect the renal pelvis or ureter, is a relatively rare disease accounting for less than 10% of all urothelial carcinomas. While radical nephroureterectomy remains the gold standard treatment for patients with upper tract urothelial carcinoma, this approach may not be suitable for some patients and for some tumors.
|
|
|
|
|
|
|
|
|
|
|
| Primary Chemoablation for the Treatment of Low-Grade Upper Tract Urothelial Carcinoma: The OLYMPUS Trial
|
| Seth P. Lerner, MD, FACS
|
| At the 2020 American Urological Association (AUA) of Seth Lerner presented on a study assessing chemoablation in upper tract urothelial carcinoma. Low-grade upper tract urothelial carcinoma is a rare disease with limited treatment options. Previous data from the compassionate use program have demonstrated that low-grade upper tract urothelial carcinoma can be chemically ablated with UGN-101.
|
|
|
|
|
|
| Identifying the Frequency of Actionable Genomic Alterations in Localized and Metastatic Upper Tract Urothelial Carcinoma
|
| Andrew Tracey, MD
|
| Andrew Tracey and colleagues characterized the prevalence of actionable genomic alterations and evidence supporting susceptibility to targeted therapies. In addition, they evaluated the prevalence of DNA damage response alterations associated with response to platinum-based chemotherapy and PD-1/PD-L1 blockade.
|
|
|
|
|
|
|
|
|
|
|
|
